{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:02:19Z","timestamp":1784599339760,"version":"3.55.0"},"reference-count":45,"publisher":"ARAN Ediciones","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hipert.2020.05.005","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T23:50:55Z","timestamp":1590537055000},"page":"169-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["El SRAA y el SARS-CoV-2: el acertijo a resolver"],"prefix":"10.20960","volume":"37","author":[{"given":"M.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.L.","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Villa-Abrille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2020.05.005_bib0230","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4812","article-title":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence?","author":"Patel","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2020.05.005_bib0235","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.hipert.2020.05.005_bib0240","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fphys.2014.00227","article-title":"From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension","volume":"5","author":"Patel","year":"2014","journal-title":"Front Physiol"},{"key":"10.1016\/j.hipert.2020.05.005_bib0245","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.hipert.2020.05.005_bib0250","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics","author":"Gurwitz","year":"2020","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.hipert.2020.05.005_bib0255","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: A potential approach for coronavirus infection therapy?","volume":"134","author":"Batlle","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.hipert.2020.05.005_bib0260","article-title":"Renin-angiotensin system blockers and the COVID-19 pandemic","volume":"75","author":"Jan Danser","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.hipert.2020.05.005_bib0265","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.hipert.2020.05.005_bib0270","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/JVI.02202-13","article-title":"TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein","volume":"88","author":"Heurich","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.hipert.2020.05.005_bib0275","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCRESAHA.116.310509","article-title":"Clinical relevance and role of neuronal AT1 receptors in ADAM17-mediated ACE2 shedding in neurogenic hypertension","volume":"121","author":"Xu","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.hipert.2020.05.005_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30158-2","article-title":"Antihypertensive drugs and risk of COVID-19?","author":"Brown","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.hipert.2020.05.005_bib0285","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.hipert.2020.05.005_bib0290","article-title":"Hypokalemia and clinical implications in patients with coronavirus disease (COVID-19)","author":"Chen","year":"2019","journal-title":"MedRxiv prepint"},{"key":"10.1016\/j.hipert.2020.05.005_bib0295","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","article-title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","volume":"63","author":"Liu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.hipert.2020.05.005_bib0300","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbrc.2004.05.114","article-title":"Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor","volume":"319","author":"Hofmann","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"10229","key":"10.1016\/j.hipert.2020.05.005_bib0305","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hipert.2020.05.005_bib0310","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.lfs.2005.09.038","article-title":"Age- and gender-related difference of ACE2 expression in rat lung","volume":"78","author":"Xie","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.hipert.2020.05.005_bib0315","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13293-017-0128-8","article-title":"Sex differences in the aging pattern of renin-angiotensin system serum peptidases","volume":"8","author":"Fern\u00e1ndez-Atucha","year":"2017","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.hipert.2020.05.005_bib0320","first-page":"1280","article-title":"Angiotensin converting enzyme 2 activity and human atrial fibrillation: Increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling","volume":"19","author":"Walters","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.hipert.2020.05.005_bib0325","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.hipert.2020.05.005_bib0330","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/01.HYP.0000237862.94083.45","article-title":"Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat","volume":"48","author":"Ocaranza","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.hipert.2020.05.005_bib0335","doi-asserted-by":"crossref","first-page":"F398","DOI":"10.1152\/ajprenal.90488.2008","article-title":"Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan","volume":"296","author":"Soler","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.hipert.2020.05.005_bib0340","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/eurheartj\/ehi114","article-title":"Myocardial infarction increases ACE2 expression in rat and humans","volume":"26","author":"Burrell","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hipert.2020.05.005_bib0345","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1042\/CS20120162","article-title":"Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: Implications for future therapeutic directions","volume":"123","author":"Burchill","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.hipert.2020.05.005_bib0350","doi-asserted-by":"crossref","first-page":"e0198144","DOI":"10.1371\/journal.pone.0198144","article-title":"Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease","volume":"13","author":"Ramchand","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.hipert.2020.05.005_bib0355","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","author":"Mancia","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2020.05.005_bib0360","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","author":"Li","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.hipert.2020.05.005_bib0365","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41581-020-0279-4","article-title":"Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic","volume":"16","author":"South","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.hipert.2020.05.005_bib0370","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2020.05.005_bib0375","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: Implications for COVID-19","author":"Kreutz","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hipert.2020.05.005_bib0380","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.114.03743","article-title":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism","volume":"64","author":"Deshotels","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.hipert.2020.05.005_bib0385","article-title":"Cardiovascular disease drug therapy, and mortality in Covid-19","author":"Mehra","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hipert.2020.05.005_bib0390","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1038\/srep07027","article-title":"Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury","volume":"4","author":"Yang","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.hipert.2020.05.005_bib0395","doi-asserted-by":"crossref","first-page":"e016509","DOI":"10.1161\/JAHA.120.016509","article-title":"Coronavirus disease 2019 (COVID-19): Do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?","volume":"9","author":"Sommerstein","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hipert.2020.05.005_bib0400","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","volume":"24","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2020.05.005_bib0405","article-title":"Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China","volume":"19","author":"Wu","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.hipert.2020.05.005_bib0410","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"28","author":"Guan","year":"2020","journal-title":"New Eng J Med"},{"key":"10.1016\/j.hipert.2020.05.005_bib0415","first-page":"30136","article-title":"Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: A systematic review and meta-analysis","volume":"piiS1201-9712","author":"Yang","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.hipert.2020.05.005_bib0420","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4683","article-title":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy","author":"Onder","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.hipert.2020.05.005_bib0425","unstructured":"Toma de Posici\u00f3n del Consejo de la Sociedad Europea de Cardiolog\u00eda [consultado 13 Mar 2020]. Disponible en: https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang"},{"key":"10.1016\/j.hipert.2020.05.005_bib0430","unstructured":"Comunicado de la Sociedad Europea de Hipertensi\u00f3n sobre COVID-19 [consultado 7 Abr 2020]. Disponible en: https:\/\/www.eshonline.org\/spotlights\/esh-letter-covid-19-2\/"},{"key":"10.1016\/j.hipert.2020.05.005_bib0435","unstructured":"Declaraci\u00f3n de la Sociedad Internacional de Hipertensi\u00f3n sobre COVID-19. Disponible en: https:\/\/ish-world.com\/news\/a\/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19\/"},{"key":"10.1016\/j.hipert.2020.05.005_bib0440","unstructured":"Comunicado de la Sociedad Espa\u00f1ola de Hipertensi\u00f3n y la Liga Espa\u00f1ola para la lucha contra la Hipertensi\u00f3n Arterial [consultado 13 Mar 2020]. Disponible en: https:\/\/www.seh-lelha.org\/covid-19\/"},{"key":"10.1016\/j.hipert.2020.05.005_bib0445","unstructured":"Declaraci\u00f3n de la Asociaci\u00f3n Americana del Coraz\u00f3n, la Sociedad Americana de Insuficiencia Card\u00edaca y el Colegio Americano de Cardiolog\u00eda [consultado 17 Mar 2020]. Disponible en: https:\/\/newsroom.heart.org\/news\/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician#.XnDMEt7Ot9I.twitter"},{"key":"10.1016\/j.hipert.2020.05.005_bib0450","unstructured":"Posici\u00f3n conjunta de las dos Sociedades de Cardiolog\u00eda y de Hipertensi\u00f3n Arterial de la Argentina (SAC\/FAC\/SAHA) [consultado 18 Mar 2020]. Disponible en: http:\/\/saha.org.ar\/files\/documents\/posicion-conjunta-SAC_FAC_SAHA-18-3-2020.pdf"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183720300568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183720300568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:16Z","timestamp":1784596516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183720300568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1889183720300568"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2020.05.005","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"El SRAA y el SARS-CoV-2: el acertijo a resolver","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2020.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SEH-LELHA. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}